Overview

PIROUETTE - A double-blind randomised controlled trial of Pirfenidone in patients with heart failure and preserved ejection fraction

This clinical trial has been designed to test whether a drug called pirfenidone leads to a reduction in heart muscle scarring and improves heart function in patients with heart failure.

Taking part involves 11 visits to the hospital and 1 telephone call, additional telephone calls will apply to women of childbearing potential to assess home pregnancy testing.

Study tests include: spectroscopy, blood tests, heart trace (ECG), echo (ultrasound scan of your heart), heart magnetic resonance imaging (MRI scan of your heart), short questionnaire, walk test, and pregnancy test if you are female and of childbearing age.

Intro video here

Trial Links

Randomised patients

0

Target patients

94

Open sites

1

Target Sites

1

Study Timeline

Study Visit Flow

Collaborators

Hospital departments taking part

The study will take part in Cardiac Departments across the country. To see if your hospital is taking part in this study please go to recruiting centres.

Study funder

This study has been funded by the National Institute for Health Research.

Study organiser

The University Hospital of South Manchester NHS Foundation Trust

Study review and approval

’The study has been reviewed by a research ethics committee, who have agreed the study is being conducted in a correct and appropriate manner. The study has also been approved by the Medicines & Healthcare products Regulatory Agency (MHRA) and the Health Research Authority (HRA).

Trial Summary and Frequently Asked Questions

Important things that you need to know

  • This clinical trial has been designed to test whether a drug called pirfenidone leads to a reduction in heart muscle scarring and improves heart function in patients with heart failure.
  • Taking part involves 11 visits to the hospital and 1 telephone call, additional telephone calls will apply to women of childbearing potential to assess home pregnancy testing.
  • Study tests include: spectroscopy, blood tests, heart trace (ECG), echo (ultrasound scan of your heart), heart magnetic resonance imaging (MRI scan of your heart), short questionnaire, walk test, and pregnancy test if you are female and of childbearing age.

Why have I been asked to take part?

You have been invited to take part because you have heart failure with preserved ejection fraction.

You do not have to take part if you do not wish to and your decision will not affect any standard of care you receive.

It is okay if you agree to take part in the study but later change your mind. You do not need to give a reason. The study doctor may also choose to withdraw you if it is necessary for your health. If you decide that you would like to withdraw from the study before the final visit all information collected up until the time of withdrawal will be included in the study analysis, unless you request that it is removed. If you do withdraw we advise that you attend the follow-up visit so that we can make sure that you are still well.

Why are we doing this research?

Heart failure with normal heart pumping function (so called “preserved ejection fraction”) is very common. However, there is no treatment that leads to an improvement in quality of life or life expectancy.

Heart muscle scarring (fibrosis) is an important process in the development of heart failure with preserved ejection fraction. We want to find out if a medicine called pirfenidone leads to a reduction in heart muscle scarring and improves heart function. Ultimately we want to find out if pirfenidone leads to improved quality of life and life expectancy of patients with heart failure.

What is pirfenidone?

Pirfenidone is currently used in patients with lung scarring. In patients with lung scarring, pirfenidone leads to a reduction in the amount of lung scarring. This leads to improved lung function, improved exercise capacity (i.e. patients can walk further before they have to stop) and improved life expectancy (i.e. patients live longer). We want to find out if pirfenidone has the same effects in patients with scarring and heart failure as it does in patients with lung scarring.

What will happen if I agree to take part?

The study will last for 1 year. We will keep a close eye on you during the study. We will phone you 1 week after starting the medication and see you in clinic, take a blood sample and do an ECG at approximately 2, 4, 8, 13, 17, 21, 26 and 39 weeks after you begin the study. After 1 year we will repeat the echo scan, the heart MRI scan (if you had 2 MRI scans at the start of the study, you will have 2 at the end), the questionnaire and the walk test. In total you will have 1 telephone call and 11 clinic visits during the study. Women of childbearing potential will also receive additional telephone calls at 24, 28, 32, 36, 44 & 48 weeks to assess home pregnancy testing.

The clinic visits will be at Wythenshawe Hospital. Travel costs will be reimbursed.

If the results of the initial tests show that you are not eligible to take part in the trial we will record your results and use them to improve the medical community’s understanding of heart failure.

Recruiting Centre and Participant Identification Centres

The following 1 sites are participating

 1 Wythenshawe Hospital

The following 4 Participant Identification Centres are taking part

 1 Manchester Royal Infirmary
 2 Salford Royal Hospital
 3 Stepping Hill Hospital
 4 Macclesfield District Hospital

Trial Team

 

Contacts

Please feel free to contact the PIROUETTE study team by any of the means below:

Telephone


00 44 (0) 151 794 9838

Address

Medicines for Children Clinical Trials Unit
Clinical Trials Research Centre
University of Liverpool
Institute of Child Health
Alder Hey Children's NHS Foundation Trust
Liverpool
L12 2AP